Lilly closes Centessa acquisition, adding narcolepsy program to neuroscience unit

Eli Lilly and Company said on June 24, 2026 that it completed its acquisition of Centessa Pharmaceuticals plc, a clinical-stage company developing orexin receptor 2 agonists as a new class of medicines for narcolepsy and potentially other sleep-wake disorders ^[1].

The announcement described Centessa as clinical-stage, meaning its medicines are still being tested and none are approved for sale. The lead program targets orexin dysfunction, and Lilly said the portfolio has "the depth to explore" narcolepsy and other conditions affected by disrupted sleep ^[1]. Financial terms of the completed deal were not disclosed in the announcement ^[1].

Carole Ho, Lilly executive vice president and president of Lilly Neuroscience, framed the science in broad terms. "The orexin system plays a fundamental role in human brain health, governing wakefulness, alertness, and the stability of sleep in ways that, when disrupted, can be profoundly disabling," she said ^[1].

"For people living with narcolepsy, that disruption is severe and life-altering," Ho added. "Orexin's reach extends further to diseases impacted by disrupted sleep, and so does the unmet need. Centessa has built a clinical portfolio with the depth to explore both, and Lilly intends to pursue that potential with urgency" ^[1].

The announcement did not name individual drug candidates from the Centessa portfolio, did not state which trial phases they are in, and did not give a dollar value for the transaction ^[1]. Lilly described itself as a 150-year-old medicine company whose current work includes diabetes care, treating obesity and its long-term effects, Alzheimer's disease, immune system disorders and cancer ^[1].

Why it matters for patients

Narcolepsy is a chronic sleep-wake disorder, and the medicines Lilly acquired are experimental. A change in ownership does not change what is available to patients today: no orexin receptor 2 agonist from this program is described as approved, and no approval date was given ^[1]. People already using existing narcolepsy treatments have no new option to consider as a result of this deal.

The announcement does not mention semaglutide or tirzepatide, and it describes no link between orexin drugs and GLP-1 drugs for weight or diabetes ^[1]. Lilly's stated interest here is the sleep-wake system, not obesity or blood sugar.

What a larger owner can change is resources. Centessa was a clinical-stage company; Lilly is a large manufacturer with an established research and commercial operation ^[1]. Whether that speeds up development is not something the announcement establishes. It also gives no information on how any future narcolepsy medicine would be priced or covered by insurance.

For patients tracking the sleep and weight side of GLP-1 use, the announcement offers nothing new. It contains no data on sleep quality, daytime sleepiness or any other outcome in people taking GLP-1 medicines, and no claim that the two areas of research are connected ^[1].

What happens next

No dated milestones were disclosed. Lilly did not announce when new trials would begin, when results from the Centessa programs might be reported, or when the company expects to seek regulatory review ^[1]. The only stated commitment is Ho's comment that Lilly "intends to pursue that potential with urgency" ^[1].

The announcement also noted that drug research, development and commercialization carry substantial risks, and that Lilly cannot guarantee the acquisition will produce commercially successful products ^[1].

Lilly's newsroom lists a separate completed acquisition of AtaiBeckley for treatment-resistant depression and other mental health conditions, and a planned appearance at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026 ^[1].